Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion type Assertion NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_head.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion evidence source_evidence_literature NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion SIO_000772 23888070 NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion wasDerivedFrom befree-20150227 NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion wasGeneratedBy ECO_0000203 NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.